Nanoflex Robotics: EIC Accelerator Bet on Magnetic Guidewires

In stroke, every minute of delay costs brain tissue, and many patients cannot get a clot removed in time because of transfer delays or a lack of on-site expertise, as the EU project file for this company puts it. Nanoflex Robotics, a 2021 spin-off of ETH Zurich's Multi-Scale Robotics Lab, wants to take the specialist out of the room: an electromagnetic field generator next to the patient steers an ultra-flexible guidewire with a magnetic tip, and the steering can be done from a console somewhere else.

The EIC selected its project, REACT, for blended finance. CORDIS records an EU contribution of €2,498,971.85, signed on 23 September 2026, for a project running from 1 October 2026 to 30 September 2028. Venture Kick and Infor Capital report the package as a €2.5 million grant plus a €10 million equity investment from the EIC Fund. The equity is an announced figure: no closing of the investment has been published. The project is one month old, so this article sets out what it promised and what can already be checked.

Steering a wire with a magnetic field

The REACT objective describes today's endovascular workflows as "highly manual" and "operator-dependent". Nanoflex's answer is to steer the wire with a magnetic field. According to the REACT objective, a compact electromagnetic field generator gives "real-time, three-dimensional control" of an ultra-flexible magnetic guidewire, which the company says allows navigation in complex anatomy "with reduced vessel stress and fewer device exchanges". CEO Matt Curran told Medical Design & Outsourcing in June 2026 that the fields are controlled "in 3D with sub-millimeter accuracy". These are the company's descriptions; no head-to-head comparison with manual navigation was found in the sources reviewed for this article.

The first product, as described in 2023 by Startupticker and Medical Device Network, is a mobile field generator that needs only a power point and a water cooling connection, so it can be wheeled between catheter labs. The system's name varies by source: "Robotic Intervention System" in CORDIS, "Remote Intervention System" at Technopark, and "Telerobotics Intervention System" on the company website.

Curran described three configurations to Medical Design & Outsourcing: bedside, with the wire advanced by hand and steered magnetically; control room, next to the operating room so the physician stays out of the X-ray field; and telerobotic, with a robot at one hospital controlled from another. REACT funds the first and prepares the third.

What the animal studies show

The strongest evidence is preclinical. Magnetics Magazine reported in April 2026 that a neurosurgeon in Arizona remotely removed clots placed in the extracranial arteries of an animal at Inselspital in Bern, more than 9,000 km away, over a secure public internet link. CTO Christophe Chautems is quoted: "Overall, we achieved 100% success with navigation and clot retrieval." Medical Design & Outsourcing dates the transatlantic study to August 2025.

The published study record is narrower. An abstract in the European Stroke Journal of 1 May 2026 (DOI 10.1093/esj/aakag023.134), from the ESOC 2026 conference, describes two live pig experiments controlled from University Hospital Zurich, 95 km away, and one from Mayo Clinic Arizona. Five of seven thrombectomy procedures achieved full clot retrieval; the two failures targeted distal clots that the catheter was too short to reach. Magnetic navigation worked in all cases. Two authors, Patrick Thurner and Tilman Schubert, disclose consulting agreements with Nanoflex Robotics. The company's "100%" refers to navigation and retrieval as it reported them; the abstract's figure for full retrieval is five of seven.

A trial that kept moving

When Nanoflex raised more than $12 million in its Series A in February 2023, Medical Device Network and Silicon Canals reported that a first-in-human trial and an FDA submission were planned for the third quarter of 2023. In February 2024 Medical Technology reported that the company planned to launch its platform in 2024. As of August 2025, according to Medical Design & Outsourcing, it was still preparing first-in-human trials, now for non-remote procedures, and Magnetics Magazine reported the same preparation in April 2026.

A search of ClinicalTrials.gov on 4 November 2026 returned no study sponsored by Nanoflex Robotics, and the FDA 510(k) database lists no clearance for the company. Trials outside the US need not appear on ClinicalTrials.gov, so this is a statement about the registry, not proof that no human has been treated. The company has announced no human procedure.

The clinical target has also shifted. The 2023 and 2024 coverage centred on remote stroke thrombectomy. The REACT objective puts peripheral vascular indications first: the project is to "complete clinical validation, regulatory approval and manufacturing readiness for EU market entry in the bedside setting for peripheral vascular indications", while teleoperation is advanced "in parallel" for later expansion to neurovascular procedures including thrombectomy, in Europe and the US.

What REACT promises

1. Magnetic steering of an ultra-flexible guidewireAnimal dataNavigation worked in all procedures of the ESOC 2026 pig study; no human data.
2. Clinical validation, bedside, peripheral vesselsNot started publiclyNo registered study found on 4 November 2026.
3. Regulatory approval for EU market entry (CE marking)Due by 2028ISO 13485 quality certification in place since the turn of 2023 and 2024; no CE mark announced.
4. Manufacturing readinessNot shownThe company has announced no production partner or volume.
5. Teleoperation for neurovascular useAnimal dataRegional and transatlantic pig thrombectomies; per the objective, neurovascular expansion is to follow REACT.

The quality certification is dated differently by two sources: a company release on BioSpace says it was achieved in December 2023, while Medical Technology reported it as received in January 2024. ISO 13485 certifies the quality management system, not the device. In March 2024, according to Asian Hospital & Healthcare Management, the company installed its first remote-ready system at the Jacobs Institute, a non-profit device innovation centre in Buffalo, New York, for usability testing, in-vivo studies, training and physician demonstrations.

The money

Nanoflex announced a Series A of more than $12 million in February 2023, led by Ascend Capital Partners with Kinled Holding and Mountain Labs, per Startupticker and Silicon Canals; Silicon Canals converted it to about €11.23 million. Medical Technology reported in February 2024 that the company had raised €18.5 million since its founding, a total no other source states. In May 2025 it won the CHF 100,000 ZKB Pionierpreis Technopark, per Technopark.

The commercial register records new shares. Moneyhouse, which reproduces the Swiss Official Gazette of Commerce, lists two ordinary capital increases that created preferred A shares, resolved on 10 March 2025 and 29 January 2026, and a third increase from conditional capital resolved on 29 April 2026. Share capital rose from CHF 147,005 to CHF 153,849. The register does not show the price paid per share, so the amount raised in those rounds is not public. Zefix, the federal register index, lists the company as existing, with its latest gazette entry on 28 October 2026.

Who else has tried

One earlier endovascular robot shows how hard the market has been. In May 2023 Siemens Healthineers stopped selling and developing its CorPath GRX robot for cardiovascular procedures and booked charges of €329 million, according to DOTmed and Reuters. Its chief financial officer, Jochen Schmitz, said the cardiology robots "did not fulfill our expectations", and that neurovascular robots were several years from market. Nanoflex's approach differs in where the control sits: per the REACT objective, the wire tip is steered by an external magnetic field. Whether that is faster or safer in people is what REACT has to show.

Why it matters for Europe

The Action Plan for Stroke in Europe 2018 to 2030, drawn up by the European Stroke Organisation and the Stroke Alliance for Europe and published in the European Stroke Journal (PubMed), sets a target of access to recanalisation therapies for 95% of eligible patients, endovascular treatment rates above 5% in every European country, and onset-to-reperfusion times under 200 minutes. The REACT objective cites transfer delays and argues for bringing "expertise to the patient rather than transferring the patient to the expert". The objective also claims the work will "strengthen Europe's leadership in medical robotics".

Nanoflex Robotics was not asked for comment for this article. The reporting is based on publicly available sources, listed below.